Amiselimod, also known as MT1303, is a potent and selective immunosuppressant and sphingosine 1 phosphate receptor modulator. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Amiselimod HCl |
| Iupac 化学名称 | Amiselimod HCl |
| 同义词 | MT-1303; MT1303; MT 1303 |
| 英文同义词 | MT-1303; MT1303; MT 1303 |
| 分子式 | C19H31ClF3NO3 |
| 分子量 | 413.91 |
| InChiKey | |
| InChi | |
| Cas号 | 942398-84-7 |
| 相关CAS号 | |
| 外观性状 | crystalline solid |
| 纯度 | 98% |
| 存储 | 3 years -20ºCpowder |
| 可溶性 | Soluble in DMSO |
| 处理方式 | |
| 运输条件 | Shipped under ambient temperature as non-hazardous chemical. |
| 海关编码 | |
| Targets | |
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study | |